Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ASI to Open Pharmaceutical Laboratory in Düsseldorf

Published: Thursday, October 04, 2012
Last Updated: Wednesday, October 03, 2012
Bookmark and Share
New laboratory will provide technical support to Ashland’s European pharmaceutical and nutraceutical customers.

Ashland Specialty Ingredients (ASI) has announced plans to open a new pharmaceutical application laboratory in Düsseldorf, Germany, in December 2012.

“With a location central to major pharmaceutical and nutraceutical customers in the region, this new lab will enable us to offer sizable value and convenience to global multinational companies as we bring on board research projects,” said Dr. Edmont Stoyanov, technical director pharmaceutical, Europe, the Middle East and Africa, ASI.

Dr. Stoyanov continued, “In addition, it will ensure our capability to realize novel ideas and developments quickly and sharpen our R&D profile. Ultimately, this will help strengthen our position as a leading innovator and deepen our relationship with originator companies.”

The new laboratory will be outfitted with the equipment covering all the processes required for classical pharmaceutical formulation and research.

Staffed with experienced pharmaceutical experts, Ashland’s Düsseldorf lab will ensure that Ashland’s customers continue to receive the high level of technical support to which they’ve grown accustomed, and open doors to promising new opportunities.

The new laboratory will be part of Ashland’s global pharmaceutical facilities network, which includes numerous laboratories and research centers worldwide, facilitating technical assistance for drug solubilization, including hot-melt extrusion and spray drying.

“Placing Ashland’s experienced pharmaceutical experts in Düsseldorf will provide the highest level of technical support for customers in areas like granulation, coating and tableting, including direct compression, roller compaction and wet granulation,” added Stoyanov.

Stoyanov continued, “We can offer our European customers quick and detailed support on all tableting issues. The lab location in Germany will accelerate and optimize the cooperation with the R&D departments of our European customers.”

Additionally, the lab will extend its services to host hands-on applications training and technical seminars for up to 20 people at a time.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!